Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Inclusion Criteria:

• Received a regimen containing one or more immuno-oncology therapeutics

• Must have experienced one or more of the following:

• One or more serious (Grade 3-4) AEs that are likely immune-related

• One or more Grade 2 dermatologic or rheumatologic AEs that are likely immune-related

• Diagnosis of a rare infection, e.g., fungal or mycobacterial, after starting IO treatment

** Note: Diagnosis of SARS-CoV-2 (COVID-19) is excluded

• Hyperprogression. Image submission for patients experiencing hyperprogression is required. For assistance in determining hyperprogression for purposes of eligibility, institutions may contact the study chair and submit images for central review

• Has not previously been registered to this study